Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Trial in Patients With Metastatic Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating Lymphocytes in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System

Next Previous
Search
Trial Profile

A Phase I/II Trial in Patients With Metastatic Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating Lymphocytes in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CISH inactivated tumour infiltrating lymphocyte cell therapy Intima Bioscience (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine; Mesna
  • Indications Brain metastases; Carcinoma; Colon cancer; Colorectal cancer; Gallbladder cancer; Gastric cancer; Gastrointestinal cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Sponsors Intima Bioscience

Most Recent Events

  • 01 May 2025 According to Intima Bioscience media release, data from the study were presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting.
  • 01 May 2025 Results presented in the Intima Bioscience Media Release
  • 17 Jan 2025 Planned End Date changed from 1 Jan 2024 to 1 Jan 2026.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top